Status message

Active context: kki_bg_colors_yellow

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC-34712) in Adolescents with Schizophrenia

Principal Investigator:
Robert
Findling

This is a phase 1, multicenter, open-label, dose-escalation trial in adolescent subjects (age 13 to 17 years) with a diagnosis of schizophrenia. This trial consists of a screening period (3 to 42 days, including washout of prohibited medications), a Dose Titration Phase, Fixed Dose Phase, and a safety follow-up.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.